Welcome to our dedicated page for Elevation Oncolo news (Ticker: ELEV), a resource for investors and traders seeking the latest updates and insights on Elevation Oncolo stock.
Elevation Oncology, Inc. (formerly Nasdaq: ELEV) has generated a range of news focused on its efforts to develop selective cancer therapies for solid tumors with significant unmet medical needs and on its subsequent corporate transformation. Company press releases highlight its concentration on antibody-drug conjugate (ADC) programs targeting Claudin 18.2 and HER3, as well as key corporate and transactional milestones.
Earlier news coverage centers on Elevation Oncology’s pipeline updates and scientific progress. The company reported clinical and preclinical developments for EO-3021, a Claudin 18.2 ADC evaluated in a Phase 1 trial for advanced gastric and gastroesophageal junction adenocarcinoma, including monotherapy and combination cohorts with ramucirumab and dostarlimab. It also announced preclinical proof-of-concept data and development plans for EO-1022, a HER3-targeting ADC designed for HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer, and described licensing of a site-specific ADC technology platform from Synaffix B.V.
Subsequent news includes strategic decisions and corporate restructuring. On March 20, 2025, Elevation Oncology disclosed that it would discontinue development of EO-3021 after evaluating updated Phase 1 data, and that it would implement a significant workforce reduction while focusing on EO-1022 and evaluating strategic options. Financial results releases have provided context on research and development spending, general and administrative expenses, restructuring charges, and cash runway expectations, as reported by the company.
A major news development occurred on June 9, 2025, when Elevation Oncology announced a definitive merger agreement under which Concentra Biosciences, LLC would acquire the company through a tender offer and subsequent merger, with shareholders receiving cash consideration and a non-tradeable contingent value right. A later Form 8-K dated July 23, 2025 confirms completion of the tender offer and merger, after which Elevation Oncology became a wholly owned subsidiary of Concentra and moved to delist and deregister its common stock.
Readers following historical ELEV news can review these updates to understand Elevation Oncology’s scientific focus on ADCs, its program-level decisions, financial disclosures, participation in scientific and investor conferences, and the steps that led to its acquisition and transition away from public trading.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced participation by CEO Shawn M. Leland in a pre-recorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022. The company focuses on precision medicines for patients with genomically defined cancers, with its lead candidate, seribantumab, targeting NRG1 fusions in solid tumors. The presentation will be available on-demand from 7:00 a.m. ET on the company's investor relations website.
Elevation Oncology, a clinical-stage biopharmaceutical company, announced that Shawn M. Leland, the CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:45 a.m. ET. The presentation will be held virtually, and interested parties can access a live webcast and replay via the company's Investor Relations website.
Elevation Oncology focuses on developing precision medicines for cancers driven by specific genomic alterations, including their lead candidate, seribantumab.
Elevation Oncology, Inc. (Nasdaq: ELEV) will present a corporate overview and engage in one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. An on-demand replay of the presentation will be available starting November 22, 2021, at 10:00 am ET on their Investor Relations website. The company focuses on precision medicines for genomically defined cancers, with lead candidate seribantumab targeting NRG1 fusions in a Phase 2 study. For more details, visit their official site.
Elevation Oncology (Nasdaq: ELEV) reported its third-quarter 2021 financial results, showcasing a net loss of $12.3 million, up from $3.0 million in Q3 2020. Cash and cash equivalents stood at $155.2 million, expected to sustain operations into Q2 2023. The CRESTONE Study for seribantumab has commenced enrollment across the US, Canada, and Australia. Notable clinical data presented indicated a 90% reduction in cancer biomarker CA19-9 in a case study of a patient with NRG1 fusion. The company anticipates completing patient enrollment in mid-2022 and presenting initial clinical results.
Elevation Oncology announced the promotion of Valerie M. Jansen, M.D., Ph.D., to the position of Chief Medical Officer, effective immediately. Jansen, previously the Vice President of Clinical Development, has significantly contributed to the company's vision and clinical programs, including the Phase 2 CRESTONE study targeting NRG1 fusions with the therapeutic seribantumab. The company aims to develop precision medicines for patients with genomically defined cancers, emphasizing the importance of genomic testing to improve treatment outcomes.
Elevation Oncology (Nasdaq: ELEV) announced a case series presentation at the AGITG 2021 Annual Scientific Meeting, highlighting its MoST study. This presentation was recognized as one of the 'Best of the Best.' A patient with treatment-refractory metastatic pancreatic cancer demonstrated lasting response to seribantumab, showing a 90% reduction in the cancer biomarker CA19-9 and a maximum tumor reduction exceeding 50% after over 9 months of treatment. The CRESTONE study, which explores seribantumab's efficacy in NRG1 fusion-positive tumors, is currently enrolling patients.
Elevation Oncology (Nasdaq: ELEV) announced that its CEO, Shawn M. Leland, will virtually present at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand from September 13, 2021, at 7:00 a.m. ET. Elevation Oncology focuses on developing precision medicines for genomically defined cancers and aims to provide individualized treatment plans.
The company's lead candidate, seribantumab, targets tumor growth driven by NRG1 fusions and is currently in Phase 2 testing.
Elevation Oncology (Nasdaq: ELEV) reported its Q2 2021 financial results on August 12, 2021, marking a pivotal period following a successful IPO that raised $106.5 million. The company’s cash reserves of $158 million are expected to fund operations into Q2 2023. R&D expenses increased to $3.9 million primarily for the CRESTONE study. The company is on track to enroll its first 20 patients in the study by early 2022 and is expanding its precision oncology pipeline through collaborations with Caris Life Sciences and other diagnostic partners.
Elevation Oncology, a clinical-stage biopharmaceutical company, will have its CEO, Shawn M. Leland, present at the 12th Annual Wedbush PacGrow Healthcare Conference on August 11, 2021, at 10:20 a.m. ET. The company focuses on developing precision medicines for cancers defined by genomic alterations. After the presentation, a recording will be available for 30 days on its Investor Relations website. Elevation's lead candidate, seribantumab, is currently in a Phase 2 study targeting NRG1 fusions.
Elevation Oncology, Inc. (Nasdaq: ELEV) announced the pricing of its initial public offering (IPO) of 6,250,000 shares at $16 each, aiming for gross proceeds of $100 million. This IPO will commence trading on the Nasdaq Global Select Market on June 25, 2021. Additionally, the underwriters have a 30-day option to purchase up to an extra 937,500 shares. The offering is set to close on June 29, 2021, pending customary conditions. Elevation is focused on precision medicine for genomically defined cancers, with its lead candidate, seribantumab, under evaluation in a Phase 2 study.
FAQ
What is the current stock price of Elevation Oncolo (ELEV)?
What is the market cap of Elevation Oncolo (ELEV)?
